Drugs / Recombinant Anti-EpCAM-CD3 Antibody
Recombinant Anti-EpCAM-CD3 Antibody
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06093698 | Dec 2023 → Jun 2026 overdue | — | ITabMed Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Anti-EpCAM-CD3 Antibody | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06093698 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Anti-EpCAM-CD3 Antibody Injection” NCT06093698 ↗ |
| Route | Intravenous | “Intravenous Infusion” NCT06093698 ↗ |